Abstract：
UNASSIGNED: To evaluate the impact of combining botulinum toxin-A (BoNT-A) injection with robot-assisted gait training (RAGT) on lower limb spasticity and motor function in children with cerebral palsy.
UNASSIGNED: A prospective study was conducted from January 2020 to January 2023, including 68 patients. Twenty patients received the combination of BoNT-A injection and RAGT, while 48 received BoNT-A injection alone. Assessments were performed before the intervention and at 1, 3, and 6 months post-injection using the Modified Tardieu Scale (MTS), sections D and E of the Gross Motor Function Measure-88 (GMFM-88), 6-minute walk test (6MWT), and 10-meter walk test (10MWT).
UNASSIGNED: Compared to the control group receiving BoNT-A alone, the combination of BoNT-A and RAGT did not significantly improve spasticity-related outcomes, including MTS scores, R1, and R2 angles (p > .05). However, the combination group demonstrated significantly improved gross motor function, particularly in walking, running (GMFM-E), short-term walking endurance (6MWT), and walking speed (10MWT) in children with cerebral palsy after the intervention (p < .05).
UNASSIGNED: While the addition of RAGT did not enhance the anti-spasticity effects of BoNT-A, it significantly improved gross motor function and walking abilities in children with cerebral palsy.
UNASSIGNED: A prospective study was conducted from January 2020 to January 2023, including 68 patients. Twenty patients received the combination of BoNT-A injection and RAGT, while 48 received BoNT-A injection alone. Assessments were performed before the intervention and at 1, 3, and 6 months post-injection using the Modified Tardieu Scale (MTS), sections D and E of the Gross Motor Function Measure-88 (GMFM-88), 6-minute walk test (6MWT), and 10-meter walk test (10MWT).
UNASSIGNED: Compared to the control group receiving BoNT-A alone, the combination of BoNT-A and RAGT did not significantly improve spasticity-related outcomes, including MTS scores, R1, and R2 angles (p > .05). However, the combination group demonstrated significantly improved gross motor function, particularly in walking, running (GMFM-E), short-term walking endurance (6MWT), and walking speed (10MWT) in children with cerebral palsy after the intervention (p < .05).
UNASSIGNED: While the addition of RAGT did not enhance the anti-spasticity effects of BoNT-A, it significantly improved gross motor function and walking abilities in children with cerebral palsy.
摘要：
■评估将肉毒杆菌毒素-A（BoNT-A）注射与机器人辅助步态训练（RAGT）相结合对脑瘫儿童下肢痉挛和运动功能的影响。
■一项前瞻性研究于2020年1月至2023年1月进行，包括68名患者。20例患者接受了BoNT-A注射和RAGT的组合，而48只接受了BoNT-A注射。使用改良的Tardieu量表（MTS）在干预前和注射后1、3和6个月进行评估，粗大运动功能测量88（GMFM-88）的D和E部分，6分钟步行测试（6MWT），和10米步行测试（10MWT）。
■与单独接受BoNT-A的对照组相比，BoNT-A和RAGT的组合并没有显着改善痉挛相关的结局，包括MTS分数,R1和R2角度(p>.05)。然而,联合组表现出显着改善粗大运动功能，尤其是在行走中,跑步（GMFM-E），短期步行耐力（6MWT），干预后脑瘫患儿的步行速度(10MWT)(p<0.05)。
■虽然添加RAGT并没有增强BoNT-A的抗痉挛作用，它显著改善了脑瘫儿童的粗大运动功能和步行能力。
■一项前瞻性研究于2020年1月至2023年1月进行，包括68名患者。20例患者接受了BoNT-A注射和RAGT的组合，而48只接受了BoNT-A注射。使用改良的Tardieu量表（MTS）在干预前和注射后1、3和6个月进行评估，粗大运动功能测量88（GMFM-88）的D和E部分，6分钟步行测试（6MWT），和10米步行测试（10MWT）。
■与单独接受BoNT-A的对照组相比，BoNT-A和RAGT的组合并没有显着改善痉挛相关的结局，包括MTS分数,R1和R2角度(p>.05)。然而,联合组表现出显着改善粗大运动功能，尤其是在行走中,跑步（GMFM-E），短期步行耐力（6MWT），干预后脑瘫患儿的步行速度(10MWT)(p<0.05)。
■虽然添加RAGT并没有增强BoNT-A的抗痉挛作用，它显著改善了脑瘫儿童的粗大运动功能和步行能力。
